LCAT and hyperinsulinemic hypoglycemia, familial, 4: More recent research has shown that recombinant LCAT effectively corrects abnormal lipoprotein profiles in LCAT knockout mice (18), and clinical phase II trials are currently underway to evaluate its potential for treating familial LCAT deficiency (https://clinicaltrials.gov/study/NCT04737720).